^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PVX-410

    i
    Other names: XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410, PVX 410, PVX-410
    Associations

    News

    Trials
    Company:
    OncoPep
    Drug class:
    CS-1 inhibitor, CD138 inhibitor, XBP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HLA-A*02 positive
    |
    Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
    2ms
    PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • PVX-410
    3ms
    A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Hiltonol (poly-ICLC) • PVX-410 • citarinostat (ACY-241)
    1year
    Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HLA-A2 positive
    |
    Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
    1year
    PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • PVX-410
    over1year
    A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Massachusetts General Hospital | Phase classification: P1b --> P1 | Trial completion date: Jun 2023 --> Sep 2024 | Trial primary completion date: Jun 2023 --> Sep 2024
    Phase classification • Trial completion date • Trial primary completion date • Epigenetic controller
    |
    lenalidomide • Hiltonol (poly-ICLC) • PVX-410 • citarinostat (ACY-241)
    almost2years
    Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Massachusetts General Hospital
    Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HLA-A2 positive
    |
    Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
    2years
    PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Massachusetts General Hospital | Phase classification: P1b --> P1 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Jun 2024
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • PVX-410
    2years
    Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Massachusetts General Hospital | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HLA-A2 positive
    |
    Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
    2years
    Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide (ASH 2023)
    There was one grade 3 trAE: specifically, a thromboembolic event in one patient who was receiving lenalidomide and despite aspirin prophylaxis, but who fully recovered. PB and marrow transcriptome profiling along with the immunogenicity studies are in progress and will be presented. We will evaluate whether PB mononuclear cells have the potential to replace BM as a surrogate for genetic and immunological surveillance in SMM, as we anticipate that further understanding of the immune alterations among patients with SMM and the response to immunomodulatory therapy may provide insight on early intervention and prevention of progression to symptomatic disease.
    Clinical • P1 data • Epigenetic controller
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • SDC1 (Syndecan 1) • XBP1 (X-box-binding protein 1)
    |
    lenalidomide • PVX-410 • aspirin • citarinostat (ACY-241)
    almost3years
    PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1b, N=20, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2022 --> Jun 2023
    Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • PVX-410